Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 3/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18827306 | 0.89 | GNAI3 (0.47) | GNAI3GNAO1GNAI1MMP8RRM1 | |
| SCHEMBL26034698 | 0.85 | MEN1 (0.51) | EPHX2MEN1KMT2ARRM1DPP7 | |
| SCHEMBL21107012 | 0.85 | KMT2A (0.46) | EPHX2MEN1KMT2AGNAI3GNAO1 | |
| SCHEMBL25698184 | 0.84 | EPHX2 (0.43) | EPHX2MEN1KMT2AGNAI3GNAO1 | |
| SCHEMBL21106763 | 0.84 | EPHX2 (0.41) | EPHX2MEN1KMT2ARRM1GLP1R | |
| SCHEMBL25885382 | 0.83 | EPHX2 (0.42) | EPHX2MEN1KMT2ARRM1DPP7 | |
| SCHEMBL25884905 | 0.82 | GLP1R (0.48) | EPHX2GNAI3GNAO1GNAI1MMP8 | |
| SCHEMBL21105771 | 0.82 | EPHX2 (0.49) | EPHX2MEN1KMT2ARRM1DPP7 | |
| SCHEMBL25972635 | 0.82 | DPP7 (0.48) | EPHX2GNAI3GNAO1GNAI1MMP8 | |
| SCHEMBL21105998 | 0.82 | KMT2A (0.44) | EPHX2MEN1KMT2AGNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EPHX2 1890/4885MEN1 4055/4885KMT2A 445/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EPHX2 1890/4885MEN1 4055/4885KMT2A 445/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | EPHX2 967/4885MEN1 1064/4885KMT2A 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.